← All trials
NCT05850364
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 22, 2023
- Primary completion
- May 1, 2024
- Completion date
- Dec 1, 2024
- First posted
- May 9, 2023
- Last posted
- Sep 26, 2023
- Enrollment
- 1440
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sinovac Biotech Co., LtdLead sponsor
- International Center for Diarrheal Disease ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.